NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Orbimed Advisors Llc sold 15,690 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $14.02, for a total transaction of $219,973.80. Following the transaction, the insider now owns 3,419,851 shares in the company, valued […]
EAM Investors LLC purchased a new position in NeuroPace, Inc. (NASDAQ:NPCE – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 141,616 shares of the company’s stock, valued at approximately $1,378,000. EAM Investors LLC owned about 0.54% of NeuroPace […]
EAM Investors LLC purchased a new stake in NeuroPace, Inc. (NASDAQ:NPCE – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 141,616 shares of the company’s stock, valued at approximately $1,378,000. A number of other institutional investors also recently modified […]
NeuroPace (NASDAQ:NPCE – Get Free Report) had its target price hoisted by Wells Fargo & Company from $9.00 to $16.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 1.14% from the company’s […]
Investment analysts at SVB Leerink began coverage on shares of NeuroPace (NASDAQ:NPCE – Get Free Report) in a research note issued to investors on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $22.00 price target on the stock. SVB Leerink’s price target indicates a potential upside of 49.15% from the company’s previous […]